| Literature DB >> 30214974 |
Alba Lucia Törnquist1, Thomas Andersson2, Jacek Winiarski3, Marita Andersson Grönlund4, Kristina Teär Fahnehjelm1,4,5.
Abstract
OBJECTIVE: To study visual pathway pathology detected by visual evoked potentials (VEPs) in patients treated with hematopoietic stem cell transplantation (HSCT) in childhood and to determine the impact of adverse ocular findings, somatic diseases, and conditioning regimens on the VEP results.Entities:
Keywords: BCVA, best corrected visual acuity; CI, cranial irradiation; CNS, central nervous system; CT, computerized tomography; CyA, cyclosporine A; GVHD, graft versus host disease; HLA, human leukocyte antigen; HSCT, hematopoietic stem cell transplantation; Hematopoietic stem cell transplantation; IOL, intra ocular lens; MRI, magnetic resonance imaging; ROP, retinopathy of prematurity; TBI, total body irradiation; VEP, visual evoked potentials; Visual acuity; Visual evoked potentials; f-TBI, fractionated total body irradiation; s-TBI, single fractio total body irradiation
Year: 2017 PMID: 30214974 PMCID: PMC6123843 DOI: 10.1016/j.cnp.2017.02.001
Source DB: PubMed Journal: Clin Neurophysiol Pract ISSN: 2467-981X
Fig. 1The patient was seated in a darkened room and instructed to fixate the centre of a reversing checkerboard pattern displayed on a monitor placed 1.3 meters in front of the eyes. Gold-pleated electrodes were attached across the scalp. The active electrode was placed at Oz (occipital midline), the reference electrode at Fz (frontal midline) and a vertex (Cz) electrode acted as ground. Each eye was examined separately with the other eye covered with a black patch. Care was taken to keep the patients as relaxed as possible to minimize artefacts and the cooperation of the subjects (fixation of the pattern) was monitored by the technician.
Fig. 2Visual evoked potential (VEP) recordings from a patient with normal VEPs (A) and a patient with abnormal responses with prolonged latencies (right eye) and also a poorly defined response (left eye) (B). Upper traces are right eyes and lower traces left eyes.
Characteristics and visual and ocular features of the eight patients with pathological visual evoked potentials (VEPs) after haematopoietic stem cell transplantation (HSCT).
| PN | Gender | Age (yrs) | Diagnosis | Conditioning therapy | GVHD | Cortico-steroids > 6 months | Occasions CyA > 250 ng/ml | Age VEP (yrs) | VEP latency RE/LE | VEP | Visual Acuity | Grade cataract/IOL | Fundus RE/LE |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 8.4 | CML | s-TBI/CY | A/C | Yes | 9 | 17 | 122/128 | N/P | 0.8/0.3 | IOL/IOL | N/N |
| 2 | F | 9.8 | AA | f-TBI/CY | A/C | Yes | 6 | 16 | 116/142 | N/P | 0.65/0.65 | 0/I | N/P* |
| 3 | M | 3.0 | CML | f-TBI/CY | A/C | Yes | 11 | 12 | 117/126 | N/P | 1.3/0.65 | IOL/IOL + Sec cat. | N/N |
| 4 | M | 6.8 | ALL | f-TBI/CY | A/C | Yes | 12 | 14 | 129/127 | P/P | 0.5/0.65 | II/II | N/N |
| 5 | M | 3.7 | AA | Busulfan/CY | No | 5 | 18 | 130/132 | P/P | 1.0/1.0 | I/I | N/N | |
| 6 | M | 10.7 | ALL | f-TBI/CY | A/C | Yes | 0 | 15 | 105/112 | N/P | 1.0/0.8 | I/I | P |
| 7 | F | 6.0 | ALL | s-TBI/CY | A | No | 9 | 15 | 127/126 | P/P | 0.8/0.65 | IOL/IOL | N/N |
| 8 | F | 10.1 | Amega | s-TBI/CY | A/C | Yes | 14 | 17 | 124/129 | N/P | 0.8/0.65 | IOL/IOL | N/N |
A: acute AA: Aplastic Anaemia, ALL: Acute Lymphoblastic Leukaemia, Amega: Amegakaryocytic thrombocytopenia, C: chronic, CML: Chronic Myeloid Leukaemia, CY: cyclophosphamide, CyA: Cyclosporin A, GVHD; Graft versus host disease, f-TBI: fractionated total body irradiation, s-TBI: single dose total body irradiation, Y:Yes, No: number, N:Normal P:Pathological, PN: patient RE: right eye, LE: left eye, µV: micro Volt, ms milli second IOL: intraocular lens, Sec cat: Secondary cataract, 0.0 =; I =; II = grades of cataract. Pink colour: pathological already pre-HSCT and also post HSCT. Yellow colour: pathological post-HSCT * Pathological fundus with retinal dragging and cryo effects due to treatment for retinopathy of prematurity (ROP).
Pathological fundi due to retinal mottling.